Published in AIDS Weekly, November 29th, 2004
Ranbaxy found "discrepancies in the documentation," which meant that it was unable to prove in studies that its generic HIV treatments are equivalent to the original medicines, the U.N. health agency said in a statement.
In India, a Ranbaxy spokesman said he had no immediate comment.
The company has already proposed dates to submit reports on new studies of the drugs, WHO said. The first...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.